Current Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now
|
|
- Angel Warner
- 5 years ago
- Views:
Transcription
1 Current Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now Eunice S. Wang, MD Roswell Park Cancer Institute Buffalo, New York, United States
2 Relapsed ALL Carries a Poor Prognosis CR after ALL induction = 85%-90% 1,2 5-year OS = 30%-50% 3,4 Up to two-thirds of patients will relapse 3,4 Salvage chemotherapy CR after 1 st salvage = 31%-45% 2,4,5 CR after 2 nd salvage = 18%-33% 6,7 Median OS = 4.5 to 6 months 2,4,5 1-year OS = 17%-24% 4,5 5-year OS = 3%-11% 2,5 Overall survival from first relapse for 248 treated AYA/adult patients aged 15 to 70 years old 5 ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; CR, complete response; OS, overall survival 1. DeAngelo DJ, et al. Leukemia. 2015;29(3): Tavernier E, et al. Leukemia. 2007;21(9): Jaime-Pérez JC, et al. Clin Lymphoma Myeloma Leuk. 2017;17(1): Kantarjian H, et al. Cancer. 2010;116(24): Oriol A, et al. Haematologica. 2010;95(4): O Brien S, et al. Cancer. 2008;113(11): Gökbuget N, et al. Blood. 2012;120(10):
3 NCCN Guidelines: Relapsed/Refractory ALL Relapsed/ refractory Ph+ ALL AYA/Adult ABL gene mutation testing Clinical trial or TKI ± chemotherapy ± HCT or TKI ± corticosteroids ± HCT or blinatumomab (failure of 2 TKIs) or inotuzumab ozogamicin (TKI intolerant or refractory) or tisagenlecleucel (patients 25 years, refractory dz, 2 relapses, failure of 2 TKIs) Ph- ALL AYA/Adult Clinical trial or chemotherapy ± HCT or blinatumomab or inotuzumab ozogamicin or tisagenlecleucel (patients 25 years, refractory dz, or 2 relapses) dz, disease; HCT, hematopoietic stem cell transplantation; NCCN, National Comprehensive Cancer Network; TKI, tyrosine kinase inhibitor NCCN Clinical Practice Guidelines in Oncology : Acute Lymphoblastic Leukemia. V Accessed November 2017.
4 Chemotherapy for Relapsed/Refractory ALL Ideal regimen is not known and depends upon timing of relapse: If relapse >2 years in CR: induction regimen similar to newly diagnosed treatments Primary resistant disease/relapse during chemo: reinduction with novel treatments After 2 nd CR, allogeneic transplant should be performed ASAP Single-agent therapy Liposomal vincristine (Ph-neg ALL that has failed 2 prior treatments) Clofarabine (ages 1-21 years that has failed 2 prior treatments) Nelarabine (relapsed T-ALL that has failed 2 prior treatments) Multiple-agent chemotherapy regimens: MOpAD, Hyper-CVAD, BFM, etc BFM, Berlin-Frankfurt-Münster; chemo, chemotherapy; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; MOpAD, methotrexate, vincristine, pegylated L-asparaginase dexamethasone NCCN Clinical Practice Guidelines in Oncology : Acute Lymphoblastic Leukemia. V Accessed November 2017.
5 Liposomal Vincristine for Relapsed Ph-neg ALL Indicated for adults with Ph-negative ALL in 2 nd relapse or progressed after 2 prior treatments Phase II trial of 65 patients (median age = 31, range = years) - Prior VCR in 100% patients - Prior allosct in 48% patients Adverse events: neurotoxicity, constipation CR/CRi ORR All patients 13 (20%) [CR in 7]* 23 (35%) 3 rd line 6/32 (19%) 4 th line 5/24 (21%) 5 th line 2/9 (22%) Relapsed 9/25 (25%) Refractory 4/29 (14%) * 8/12 - (MRD negative) allosct, allogeneic hematopoietic stem cell transplantation; CI, confidence interval; CRi, complete response with incomplete hematologic recovery; MRD, minimal residual disease; ORR, objective response rate; VCR, vincristine O'Brien S, et al. J Clin Oncol. 2013;31(6):
6 Clofarabine for Relapsed Pediatric ALL Purine nucleoside metabolic inhibitor Pediatric patients (1-21 years) with relapsed/refractory ALL after at least 2 prior regimens Dose: 52 mg/m 2 IV over 2 hours for 5 consecutive days Open-label, single-arm trial of 61 pediatric patients (62% >2 prior treatments, 30% prior allosct) 1 - Overall response rate 20.7% (CR 11.5%, CRp 8.2%) - Median duration of CR/CRp = 10.7 weeks - No survival data Toxicities: 2 Febrile neutropenia (55%), infection (83%), nausea/vomiting (73%-78%), diarrhea (56%), rash (38%), elevated LFTs (36%-43%) CRp, complete response without platelet recovery; IV, intravenous; LFTs, liver function tests; mg/m 2, milligrams per square meter 1. Jeha S, et al. J Clin Oncol. 2006;24(12): Clofarabine [package insert]. Cambridge, MA: Genzyme Corporation; September 2014.
7 Nelarabine for Relapsed T-ALL Purine nucleoside antimetabolite similar to cytarabine T-cell ALL & lymphoblastic lymphoma not responded/relapsed after 2 prior treatments Single-arm phase II trial of 126 adult patients with relapsed/refractory T-ALL/T-LBL Complete response = 36% 80% of patients achieving CR underwent subsequent allosct Overall survival: 24% at 1 year, 11% at 6 years, high relapse rates after allosct Toxicities: Neurotoxicity, myelosuppression, infection, asthenia LBL, lymphoblastic lymphoma Gökbuget N, et al. Blood. 2011;118(13):
8 Harnessing the Immune System for ALL Therapy Antibodies - Blinatumomab - Inotuzumab Macrophage - Vaccine Leukemia cell Helper T cell - Vaccine Natural killer cell Genetically modified CAR T cells CAR, chimeric antigen receptor
9 Blinatumomab vs Chemotherapy for RR ALL Blinatumomab Chemo CR/CRi/CRp 43.9% 24.6% CR 33.6% 15.7% CRi/CRp 10.4% 9.0% mo, month; RR, relapsed/refractory Kantarjian H, et al. N Engl J Med. 2017;376(9):
10 Blinatumomab Beneficial Across Subgroups no., number; yr, year Kantarjian H, et al. N Engl J Med. 2017;376(9):
11 Inotuzumab Ozogamicin (IO) Results in High Response Rates Inotuzumab Chemo CR/CRi/CRp 80.7% 29.4% CR 35.8% 17.4% CRi/CRp 45% 11.9% IO, inotuzumab ozogamicin Kantarjian H, et al. N Engl J Med. 2016;375(8):
12 Adverse Events Associated With IO Grade 3 or higher Thrombocytopenia Grade 3 or higher Febrile Neutropenia Veno-occlusive Disease (any) Inotuzumab Ozogamicin Salvage Chemotherapy 37% 59% 24% 49% 11% (n = 15) (2 deaths) 1% (n = 1) pts, patients; VOD, veno-occlusive disease Kantarjian H, et al. N Engl J Med. 2016;375(8):
13 Salvage IO + Mini-Hyper-CVD for Ph-neg B-ALL Overall and Relapse-Free Survival Overall Survival by Relapse Status N = 59 patients ORR = 78% VOD = 15% pts Median OS = 11 mos CVD, cyclophosphamide, dexamethasone, methotrexate, cytarabine Jabbour E, et al. JAMA Oncology Aug 31. [Epub ahead of print].
14 Advent of CAR T-Cell Therapy for ALL On Friday May 28, 2010 just a few weeks after my 5 th birthday, I was diagnosed with standardrisk pre-b ALL In April 2012 I was enrolled into a phase I clinical trial at Children s Hospital of Philadelphia (CHOP). I was the first pediatric patient to receive genetically modified T cells to help fight my leukemia. I was very sick after and was in the pediatric intensive care for several weeks on a ventilator In May 2012 I found out that the new cells worked and that I was in remission!! I came home from the hospital June 1, 2012 and have been doing very well! Love, Emily Emily Whitehead Foundation. Accessed November 28, 2017.
15 Single-Center Trial of CTL019 (Tisagenlecleucel) in RR B-ALL 30 patients with RR B-ALL (follow-up 2 years) Characteristics - Ages 5-60 yrs old - 18 (60%) had prior allosct - 3 (10%) had refractory ALL - 22 (73%) had 2 relapses Responses - 27 pts (90%) achieved CR in 1 month - 2 of 3 pts with prior blinatumomab treatment responded Maude SL, et al. N Eng J Med. 2014;371(16):
16 Phase II Trial of Tisagenlecleucel in Pediatric Patients With RR ALL First pediatric global CAR T-cell therapy registration trial Single-arm, open-label, multicenter phase II study 25 centers in US, Canada, EU, Australia, and Japan Patients aged 3-23 years old CD19+ B-ALL primary refractory or relapsed or ineligible for allosct 5% marrow blasts by morphology Single dose of 2-5 x 10 6 transduced autologous CTL019 cells/kg (max 2.5 x 10 8 ) IV manufactured at a centralized facility Endpoint: CR + CRp at 3 months Buechner J, et al. Haematologica. 2017;102(Suppl 2): Abstract S476.
17 Clinical Efficacy of Tisagenlecleucel Median age 12 years (range 3-23 yrs) Median of 3 prior therapies (59% prior allosct) Among 63 evaluable patients: CR/CRi (MRD neg) 83% Single dose of 2-5 x 10 6 per kg transduced autologous T cells CD19 CD19 Survival Survival 79% 89% CTL019 Autologous T-cell Buechner J, et al. Haematologica. 2017;102(Suppl 2): Abstract S476.
18 Adverse Events With Tisagenlecleucel Effects Percentage Pts Comments Cytokine Release Syndrome 78% Gr 3 (21%), Gr 4 (27%) No grade 5 38% Rx tocilizumab (anti-il-6r antibody) Neutropenic fever 60% -- Hypotension 22% --- Hypoxia 16% --- Neuropsychiatric 15% No grade 4 No cerebral edema Gr, grade Buechner J, et al. Haematologica. 2017;102(Suppl 2): Abstract S476.
19 AlloSCT vs Chemotherapy for ALL Relapse Auto, autograft; MUD, matched unrelated donor; O/E, observed/expected; sib, sibling Fielding AK, et al. Blood. 2007;109(3):
20 Comparison of T-Cell Directed Therapy for ALL Blinatumomab (Antibody) CAR T Cells AlloSCT T-cell source Patient (normal cells) Donor Cells manipulation In-vivo Ex-vivo Target CD 19 on leukemia B cells Multiple Status pretreatment Low tumor burden Low tumor burden CR Administration 24 hr infusion x 28 d 1-3 infusions 1 infusion Activity duration Short Long Permanent CR 40% 1 90% 2 N/A Potential for cure No? Yes Main toxicity CRS (minimal-modest) CRS (modest severe) GVHD CRS, cytokine release syndrome; GVHD, graft-versus-host disease 1. Kantarjian H, et al. N Engl J Med. 2017;376(9): Maude SL, et al. N Eng J Med. 2014;371(16):
21 Relapsed Ph+ ALL: Selection of TKI Therapy BCR-ABL1 Resistance Mutations Adverse Event Spectrum Mutation Y253H, E255KV, F359VCI F317LVIC, T315A, V299L E255KV, F317LVIC, F359VCL,T315A, Y253H T315I CNS penetration Imatinib < dasatinib levels in CSF CNS, central nervous system; CSF, cerebrospinal fluid Best TKI Dasatinib Nilotinib Bosutinib Ponatinib Column 2 Ponatinib Elevated Pancreatic Enzymes Hypertension Skin toxicity Thrombotic events Nilotinib Elevated Pancreatic Enzymes Indirect hyperbilirubinemia QT prolongation Cardiovascular events Common Effects Myelosuppression Transaminitis Electrolyte Δ Imatinib Edema/fluid retention Myalgias Hypophosphatemia GI (diarrhea, N/V) Dasatinib Pleural/pericardial effusions Bleeding risk Pulmonary arterial Hypertension Bosutinib GI (diarrhea, N/V) Headache Rash Imatinib [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; August Dasatinib [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; October Nilotinib [package insert]. East Hanover, NJ: Novartis; October Bosutinib [package insert]. New York, NY: Pfizer Labs; September Ponatinib hydrochloride [package insert]. Cambridge, MA: ARIAD Pharm Inc.; August 2016.
22 Relapsed Ph+ ALL: TKI Plus Chemotherapy Dasatinib + Hyper-CVAD therapy Overall Survival ORR = 91% Cytogenetic response = 84% Molecular response = 42% Major molecular response = 35% 3-year OS for Ph+ ALL = 26% CML-BC, chronic myeloid leukemia in blast crisis Benjamin O, et al. Am J Hematol. 2014;89(3):
23 Blinatumomab for Relapsed Ph+ ALL Open-label phase II study of adults relapsed/refractory to second-generation TKI and/or intolerant of TKI 45 patients Rx blinatumomab monotherapy 36% CR/CRi after 2 cycles 88% of responders achieved MRD response Median RFS = 6.7 mos Median OS = 7.1 mos 44% to allosct RFS, relapse-free survival Martinelli G, et al. J Clin Oncol. 2017;35(16):
24 Blinatumomab + TKI for Relapsed Ph+ ALL Overall survival 9 Ph+ ALL and 3 CML blast crisis Failed 1 chemotherapy and 1 TKI Treatment: blinatumomab plus ponatinib (n = 8), dasatinib (n = 3), bosutinib (n = 1) - Complete hematologic response = 50% - Cytogenetic response = 71% - Molecular response = 75% - 2 cases of cytokine release syndrome - Median FU = 8 mo - Median OS = not reached - 1-year OS = 73% m, median; NR, not reported Assi R, et al. Clin Lymph Myeloma Lek. 2017;17(12):
25 Inotuzumab for Relapsed Ph+ ALL Kantarjian H, et al. N Engl J Med. 2016;375(8):
26 Summary: Relapsed/Refractory ALL Ph-positive and negative ALL Blinatumomab (B-ALL) (after failure of two TKIs) Inotuzumab ozogamicin (B-ALL) (TKI intolerant/refractory) Tisagenlecleucel ( 25 years, refractory, 2 relapses, failure of 2 TKIs) Chemotherapy (liposomal vincristine, clofarabine, nelarabine) Multiple-agent chemotherapy regimens Ph-positive ALL TKIs (dasatinib, imatinib, ponatinib, nilotinib, bosutinib) (first priority) TKIs plus chemotherapy Other options as listed for Ph-negative ALL NCCN Clinical Practice Guidelines in Oncology : Acute Lymphoblastic Leukemia. V Accessed November 2017.
27 Images from: Morgan AS, et al. Blood. 2013;121:3546.
Inotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationImmunotherapies in Acute Lymphoblastic Leukaemia. Professor David Ritchie Royal Melbourne Hospital
Immunotherapies in Acute Lymphoblastic Leukaemia Professor David Ritchie Royal Melbourne Hospital Blinatumomab Cases Case 1: Mr BE 30 year old male Aged 17, diagnosed Philadelphia negative B-ALL in Nov
More informationBESPONSA (inotuzumab ozogamicin)
BESPONSA (inotuzumab ozogamicin) Fact Sheet BESPONSA (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody (mab) targeting CD22, a cell surface antigen expressed
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationManagement of Acute Lymphoblastic Leukemia
Management of Acute Lymphoblastic Leukemia Joseph C. Alvarnas, MD City of Hope Comprehensive Cancer Center Acute Lymphoblastic Leukemia (ALL) Approximately 6,000 patients per year diagnosed with ALL 60%
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationTiming and complications of allogeneic stem cell transplant in Ph + ALL
Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb
More informationPharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions
Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions Clin. Invest. (2012) 2(7), 715 731 In adults, acute lymphoblastic leukemia (ALL) is an
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationCAR T-Cell Therapy for Your Patients: What You Need To Know
CAR T-Cell Therapy for Your Patients: What You Need To Know Marco L. Davila, MD, PhD Associate Member, Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director Cell Therapy Facility H.
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationFACULTY TRAINING TRANSCRIPT
FACULTY TRAINING TRANSCRIPT PROGRAM CURRICULUM REVIEWED BY: B. DOUGLAS SMITH, MD Professor of Oncology Johns Hopkins University, School of Medicine Baltimore, MD JONATHAN WEBSTER, MD Instructor of Oncology
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationCML Clinical Case Scenario
CML Clinical Case Scenario Neil Shah, MD, PhD Edward S. Ageno Distinguished Professor in Hematology/Oncology Leader, Hematopoietic Malignancies Program Helen Diller Family Comprehensive Cancer Center at
More informationThe use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia
NOVEL APPROACHES TO ACUTE LYMPHOBLASTIC LEUKEMIA The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia Daniel J. DeAngelo 1 1 Harvard Medical School, Dana-Farber Cancer
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationNEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationIntroduction. Methods. The University of North Carolina Chapel Hill Investigational Review Board approved this study.
Abstract Background: Salvage chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia (AML) are associated with complete response rates of 30-60%. Determining the superiority
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationICLUSIG (ponatinib) oral tablet
ICLUSIG (ponatinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationLondon Cancer ALL guidelines
London Cancer ALL guidelines Page 1 of 7 CONTENTS OVERVIEW - main points in ALL management... 3 AGE-SPECIFIC THERAPEUTIC APPROACHES... 4 SPECIFIC THERAPEUTIC PROBLEMS... 5 SUPPORTIVE CARE... 6 PATIENTS
More informationInotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
812013TAH0010.1177/2040620718812013Therapeutic Advances in HematologyJ.M. Savoy, M.A. Welch et al. review-article2018 Therapeutic Advances in Hematology Review Inotuzumab ozogamicin for the treatment of
More informationTreatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine
Treatment of High-risk Acute Lymphoblastic Leukemia With Precision Medicine Minimal Residual Leukemia Level: Independent Prognostic Indicator Leukemic cell Tumor burden Growth potential Drug resistance
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationSubject: Dasatinib (Sprycel ) Tablets
09-J1000-43 Original Effective Date: 01/01/12 Reviewed: 01/10/18 Revised: 02/15/18 Subject: Dasatinib (Sprycel ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia February 4, 2016
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Blinatumomab (Blincyto) for Acute Lymphoblastic Leukemia February 4, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationAxicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line
NIHR Innovation Observatory Evidence Briefing: August 2017 Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line NIHRIO
More informationAllogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors Allogeneic haematopoietic stem cell transplant (allosct) is an effective therapeutic
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationBlinatumomab (Blincyto) Ph+BCP-ALL
The Committee also deliberated on the results of the manufacturer-submitted propensity score analysis, which compared efficacy outcomes in the ALCANTARA study with a historical comparator study. perc acknowledged
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationTreatment of Adult Acute Lymphoblastic Leukemia (ALL) With a
Focus on Emerging Investigational and Targeted Therapies Review Article [1] September 12, 2012 By Michael S. Mathisen, PharmD [2], Elias Jabbour, MD [3], and Hagop M. Kantarjian, MD [4] In this review,
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationFDA Briefing Document. Oncologic Drugs Advisory Committee March 21, 2012
FDA Briefing Document Oncologic Drugs Advisory Committee March 21, 2012 NDA: 202497 Vincristine Sulfate Liposomal Injection (Marqibo) Talon Therapeutics DISCLAIMER STATEMENT The attached documents contain
More informationThe speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.
Hana Safah MD Professor of Medicine Tulane University School of Medicine Director of the SCT program, Tulane Medical Center The speaker has no financial relationships with a commercial interest to disclose
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationNEW FDA DRUG APPROVALS
NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationKymriah (tisagenlecleucel)
Kymriah (tisagenlecleucel) Policy Number: Original Effective Date: MM.02.036 06/01/2018 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2018 Section: Medicine Place(s) of Service:
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationOn behalf of Study SGI Investigators Team
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More information